Pfizer Rid Mousse Pediculicide Approved Under "NDA Deviation"
This article was originally published in The Rose Sheet
Executive Summary
FDA approved an "NDA Deviation" (21-043) for Pfizer's Maximum Strength Rid Mousse aerosolized foam lice treatment March 7.
You may also be interested in...
Bayer Rid Pediculicide Marketing Emphasis On Mousse Launch
Bayer Consumer Care's inaugural marketing efforts for the newly acquired Rid brand will focus on Maximum Strength Rid Mousse aerosolized foam lice treatment, which began shipping June 22.
Bayer Rid Pediculicide Marketing Emphasis On Mousse Launch
Bayer Consumer Care's inaugural marketing efforts for the newly acquired Rid brand will focus on Maximum Strength Rid Mousse aerosolized foam lice treatment, which began shipping June 22.
Non-Monograph Drugs Interim Marketing Preservation Urged By CHPA
FDA's proposed rule on "material time, material extent" criteria for inclusion of drug conditions in the OTC review would "effectively terminate" the monograph process, CHPA maintains in a March 22 letter to the agency.